QIAGEN N.V.

Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.